NASDAQ:BRCN - Nasdaq - CA1208311029 - Common Stock - Currency: USD
0.44
-0.02 (-4.78%)
The current stock price of BRCN is 0.44 USD. In the past month the price decreased by -36.23%. In the past year, price decreased by -80.87%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
SHW | SHERWIN-WILLIAMS CO/THE | 31.86 | 91.10B | ||
ECL | ECOLAB INC | 37.99 | 73.49B | ||
DD | DUPONT DE NEMOURS INC | 16.08 | 29.01B | ||
PPG | PPG INDUSTRIES INC | 14.33 | 25.89B | ||
IFF | INTL FLAVORS & FRAGRANCES | 17.78 | 19.88B | ||
RPM | RPM INTERNATIONAL INC | 22.57 | 14.90B | ||
SQM | QUIMICA Y MINERA CHIL-SP ADR | 4.94 | 9.95B | ||
EMN | EASTMAN CHEMICAL CO | 10.08 | 9.53B | ||
AXTA | AXALTA COATING SYSTEMS LTD | 13.89 | 7.14B | ||
ALB | ALBEMARLE CORP | N/A | 7.08B | ||
NEU | NEWMARKET CORP | 12.94 | 6.13B | ||
CE | CELANESE CORP | 7.82 | 5.98B |
Burcon NutraScience Corp. engages in the development of plant proteins and ingredients for use in the food and beverage industries in Canada. The company is headquartered in Vancouver, British Columbia and currently employs 19 full-time employees. The firm is engaged in development of plant protein extraction and purification technology in the field of functional, renewable plant proteins. The firm has a portfolio of composition, application and process patents covering plant-based proteins derived from pea, canola, soy, hemp and sunflower seeds. The firm has developed pea proteins that it has branded Peazazz and Peazac, and over three canola protein products, Puratein, Supertein and Nutratein. The firm also includes CLARISOY, which is a soy protein. The Company’s subsidiaries include Burcon NutraScience (MB) Corp. and Burcon NutraScience Holdings Corp.
BURCON NUTRASCIENCE CORP
1946 Broadway W
Vancouver BRITISH COLUMBIA CA
CEO: Johann Franz Tergesen
Employees: 19
Phone: 16047330896.0
The current stock price of BRCN is 0.44 USD. The price decreased by -4.78% in the last trading session.
The exchange symbol of BURCON NUTRASCIENCE CORP is BRCN and it is listed on the Nasdaq exchange.
BRCN stock is listed on the Nasdaq exchange.
11 analysts have analysed BRCN and the average price target is 1.67 USD. This implies a price increase of 279.09% is expected in the next year compared to the current price of 0.44. Check the BURCON NUTRASCIENCE CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
BURCON NUTRASCIENCE CORP (BRCN) has a market capitalization of 47.84M USD. This makes BRCN a Nano Cap stock.
BURCON NUTRASCIENCE CORP (BRCN) currently has 19 employees.
BURCON NUTRASCIENCE CORP (BRCN) has a resistance level at 0.5. Check the full technical report for a detailed analysis of BRCN support and resistance levels.
The Revenue of BURCON NUTRASCIENCE CORP (BRCN) is expected to grow by 489.89% in the next year. Check the estimates tab for more information on the BRCN EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
BRCN does not pay a dividend.
BURCON NUTRASCIENCE CORP (BRCN) will report earnings on 2022-11-14.
BURCON NUTRASCIENCE CORP (BRCN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.07).
ChartMill assigns a technical rating of 1 / 10 to BRCN. When comparing the yearly performance of all stocks, BRCN is a bad performer in the overall market: 93.25% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to BRCN. While BRCN has a great health rating, there are worries on its profitability.
Over the last trailing twelve months BRCN reported a non-GAAP Earnings per Share(EPS) of -0.07. The EPS decreased by -416.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | -4537.09% | ||
ROA | -43.62% | ||
ROE | N/A | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 85% to BRCN. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of -26.67% and a revenue growth 489.89% for BRCN